We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...

In interviews with Reuters, eight U.S. obesity specialists at universities and large health systems described a different ...

Powerful weight-loss drugs like Wegovy and Zepbound have driven nearly $1 trillion in market-capitalization gains, with most of those gains flowing to Eli Lilly and Novo Nordisk, the dominant players ...

After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...

These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates appetite and digestion. The medications control blood sugar and help people ...

Obesity pill data released by Viking Therapeutics Inc. and AstraZeneca Plc at a big conference foreshadowed an increasingly competitive landscape for weight-loss therapies, sending down shares of ...

Incyte filed a lawsuit to try to block the launch of Leqselvi, claiming that the drug infringed a US patent (No. 9,662,335) ...

Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025.

The Danish drugmaker plans to introduce a combination drug, CagriSema, that could result in 25% weight loss — higher than ...

Viking Therapeutics (VKTX) surges on promising obesity drug results. Explore key price levels and analyst insights in this detailed analysis.